REFRACTORY DIFFERENTIATED THYROID GLAND CARCINOMA
Clinical trials for REFRACTORY DIFFERENTIATED THYROID GLAND CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY DIFFERENTIATED THYROID GLAND CARCINOMA trials appear
Sign up with your email to follow new studies for REFRACTORY DIFFERENTIATED THYROID GLAND CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for Hard-to-Treat thyroid cancer: drug XL092 enters human trials
Disease control Recruiting nowThis phase 2 trial tests a drug called XL092 in 33 people with advanced thyroid cancer that has stopped responding to radioiodine therapy. XL092 works by blocking a protein that helps cancer cells grow. The study aims to see if the drug can slow or stop cancer progression.
Matched conditions: REFRACTORY DIFFERENTIATED THYROID GLAND CARCINOMA
Phase: PHASE2 • Sponsor: Jochen Lorch • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New study pits two drug combos against stubborn thyroid cancer
Disease control Recruiting nowThis phase III trial is for people with a specific type of thyroid cancer (BRAF V600E-mutated) that doesn't respond to radioactive iodine. It compares two treatment options: a combination of dabrafenib and trametinib versus cabozantinib alone. The goal is to see which is safer an…
Matched conditions: REFRACTORY DIFFERENTIATED THYROID GLAND CARCINOMA
Phase: PHASE3 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC